Moxifloxacin Advantages and Clinical Applications

Antimicrobial Spectrum and Efficacy

Moxifloxacin has a broad spectrum of activity against both Gram-positive and Gram-negative pathogens, with improved coverage against Gram-positive cocci compared to older fluoroquinolones 1, 2
Moxifloxacin exhibits potent activity (approximately 90% susceptibility) against anaerobes, particularly Bacteroides species, making it effective for mixed infections 3, 4
In Taiwan, studies showed that more than 85% of Enterobacteriaceae from intra-abdominal infections were susceptible to moxifloxacin, with better in vitro activity than ciprofloxacin and levofloxacin 5, 6

Moxifloxacin has relatively greater bioavailability, longer half-life (approximately 12 hours), and higher peak serum concentration (Cmax) than ciprofloxacin 3
It achieves high penetration and accumulation in gastrointestinal mucosa, abdominal tissue, abdominal exudate, and abscess fluid at concentrations above the MIC90 for key pathogens 3, 4

Moxifloxacin is recommended as a first-line monotherapy for empiric treatment of complicated intra-abdominal infections (cIAIs) 3, 7
Sequential therapy with IV to oral once-daily moxifloxacin is safe, well-tolerated, and as efficacious as multi-dose regimens of IV piperacillin/tazobactam followed by oral amoxicillin/clavulanic acid 7
Randomized clinical studies have demonstrated the safety and efficacy of moxifloxacin monotherapy in patients with cIAIs 3, 7

The Infectious Diseases Society of America (IDSA) recommends moxifloxacin monotherapy for mild-to-moderate complicated intra-abdominal infections due to its broad aerobic and anaerobic coverage 8
In regions with fluoroquinolone resistance rates >20% among certain bacteria, neither moxifloxacin nor levofloxacin should be used empirically for intra-abdominal infections 8

In areas where fluoroquinolone resistance is <20% and ESBL-producing bacteria <10%, moxifloxacin remains appropriate first-line therapy 8